What does excl mean in trading?
EXCL: Strong Bearish Ichimoku; Bearish Stochastic (%K = 28.14); Bullish MACD (MACD Level = -40.82); Excl has a potential of swing trading with a 1:2 risk/reward ratio. It can also be seen that excl are trying to make a pattern which is double pattern.
Where can I buy shares of Exel?
Shares of EXEL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here.
Where can I buy Exelixis stock?
Shares of EXEL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Exelixis' stock price today?
What are analysts'1-year price targets for Exelixis'stock?
9 equities research analysts have issued 1-year price objectives for Exelixis' stock. Their forecasts range from $26.00 to $36.00. On average, they anticipate Exelixis' stock price to reach $30.75 in the next twelve months. This suggests a possible upside of 75.2% from the stock's current price.
Is Exelixis a buy right now?
7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Exelixis in the last year. There are currently 7 buy ratings for...
Are investors shorting Exelixis?
Exelixis saw a increase in short interest during the month of May. As of May 15th, there was short interest totaling 9,990,000 shares, an increase...
When is Exelixis' next earnings date?
Exelixis is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022. View our earnings forecast for Exelixis .
How were Exelixis' earnings last quarter?
Exelixis, Inc. (NASDAQ:EXEL) released its quarterly earnings results on Tuesday, May, 10th. The biotechnology company reported $0.21 earnings per s...
What guidance has Exelixis issued on next quarter's earnings?
Exelixis issued an update on its FY 2022 earnings guidance on Tuesday, May, 24th. The company provided earnings per share (EPS) guidance of for the...
What price target have analysts set for EXEL?
7 Wall Street analysts have issued twelve-month price objectives for Exelixis' stock. Their forecasts range from $28.00 to $42.00. On average, they...
Who are Exelixis' key executives?
Exelixis' management team includes the following people: Dr. Stelios Papadopoulos Ph.D. , Co-Founder & Independent Chair of the Board (Age 74, P...
What is Michael M. Morrissey's approval rating as Exelixis' CEO?
32 employees have rated Exelixis CEO Michael M. Morrissey on Glassdoor.com . Michael M. Morrissey has an approval rating of 79% among Exelixis' em...
Who are some of Exelixis' key competitors?
Some companies that are related to Exelixis include Amgen (AMGN) , Gilead Sciences (GILD) , Regeneron Pharmaceuticals (REGN) , Vertex Pharmaceu...
Ideas
Profile
WEAK SUPPORT AT 2950 WEAK RESISTANCE AT 3160 I PREFER YELLOW TRADING PLAN Disclaimer: This information is for educational purposes and is not an investment recommendation or representative of professional expertise. This analysis used herein is for illustration purposes only.
How much did Exelixis stock fall in 2021?
PT XL Axiata Tbk engages in the provision of telephony services. It offers the following products and services: cellular mobile network, internet services provider, closed fixed network services, internet telephony service for public interest license, internet interconnection services, and packet switched local fixed network license.
Is Exelixis a negative stock?
The Exelixis stock price fell by -0.78% on the last day (Thursday, 8th Jul 2021) from $17.97 to $17.83. and has now fallen 3 days in a row. During the day the stock fluctuated 4.60% from a day low at $17.60 to a day high of $18.41. The price has been going up and down for this period, and there has been a -19.76% loss for the last 2 weeks. Volume fell on the last day along with the stock, which is actually a good sign as volume should follow the stock. On the last day, the trading volume fell by -408 thousand shares and in total, 3 million shares were bought and sold for approximately $54.89 million.
Is Exelixis stock a sell signal?
Exelixis holds several negative signals and is within a very wide and falling trend, so we believe it will still perform weakly in the next couple of days or weeks. We therefore hold a negative evaluation of this stock. Due to some small weaknesses in the technical picture we have downgraded our analysis conclusion for this stock since the last evaluation from a Sell to a Strong Sell candidate.
Is Exelixis oversold?
There are few to no technical positive signals at the moment. The Exelixis stock holds sell signals from both short and long-term moving averages giving a more negative forecast for the stock. Also, there is a general sell signal from the relation between the two signals where the long-term average is above the short-term average. On corrections up, there will be some resistance from the lines at $17.51 and $19.89. A break-up above any of these levels will issue buy signals. A sell signal was issued from a pivot top point on Tuesday, November 02, 2021, and so far it has fallen -22.03%. Further fall is indicated until a new bottom pivot has been found. Furthermore, there is currently a sell signal from the 3 month Moving Average Convergence Divergence (MACD). Volume rose on falling prices yesterday. This may be an early warning and the stock should be followed more closely.
When is Exelixis earnings call?
Exelixis is oversold on RSI14 (24). Some stocks may drop long and hard while being oversold on RSI before turning, which increases the general risk.
What is the ticker symbol for Exelixis?
How can I listen to Exelixis' earnings call? Exelixis will be holding an earnings conference call on Thursday, August 5th at 5:00 PM Eastern. Interested parties can register for or listen to the call using this link or dial in at 404-537-3406 with passcode "7296685".
How much does Exelixis make?
Exelixis trades on the NASDAQ under the ticker symbol "EXEL."
What is the PEG ratio of Exelixis?
How much money does Exelixis make? Exelixis has a market capitalization of $5.22 billion and generates $987.54 million in revenue each year. The biotechnology company earns $111.78 million in net income (profit) each year or $0.35 on an earnings per share basis.
Is Exelixis a buy or sell company?
Exelixis has a PEG Ratio of 0.81. PEG Ratios below 1 indicate that a company could be undervalued.
Does Exelixis pay dividends?
Exelixis has received a consensus rating of Buy. The company's average rating score is 2.91, and is based on 10 buy ratings, 1 hold rating, and no sell ratings.
Analyst Opinions
Exelixis does not currently pay a dividend.
Research Reports
The Equity Summary Score is an accuracy-weighted sentiment derived from the ratings of independent research providers on Fidelity.com. It uses the past relative accuracy of the providers in determining the emphasis placed on any individual opinion. Learn More....
Compare
This generated report* compiles independent, third-party information highlighting key fundamental and technical data, analyst opinions, stock price movement, earnings data, and industry comparisons. Available only to Fidelity customers.
Nasdaq Global Select
Sorry - there is currently no Compare information available for this stock.
Environmental, Social, and Governance Rating
A development-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics for the treatment of cancer and other serious diseases.
Business Summary
"B" score indicates good relative ESG performance and an above-average degree of transparency in reporting material ESG data publicly and privately. Scores range from AAA to D.
